Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.63 [0.47, 0.84] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | crucial | - |
deaths (OS) (extension) | 0.68 [0.53, 0.87] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
PFS (extension) | 0.61 [0.50, 0.75] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.58 [0.46, 0.73] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
objective responses (ORR) | 3.77 [2.43, 5.86] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
STRAE (any grade) | 0.67 [0.41, 1.09] | | < 1 | | 0% | 1 study (1/-) | 94.7 % | NA | not evaluable | | non important | - |
STRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 1.62 [1.07, 2.46] | | < 1 | | 0% | 1 study (1/-) | 1.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.84 [0.54, 1.30] | | < 1 | | 0% | 1 study (1/-) | 78.4 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 1.84 [0.06, 55.23] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.74 [0.39, 1.40] | | < 1 | | 0% | 1 study (1/-) | 82.1 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 1.85 [0.17, 20.50] | | < 1 | | 0% | 1 study (1/-) | 31.0 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 1 study (1/-) | 73.6 % | NA | not evaluable | | non important | - |
Chills TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 0.19 [0.06, 0.58] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Cough TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.92 [0.32, 2.66] | | < 1 | | 0% | 1 study (1/-) | 56.2 % | NA | not evaluable | | non important | - |
Dry skin TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 0.46 [0.02, 13.75] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.30 [0.03, 2.95] | | < 1 | | 0% | 1 study (1/-) | 84.6 % | NA | not evaluable | | non important | - |
Headache TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 2.78 [0.29, 26.92] | | < 1 | | 0% | 1 study (1/-) | 19.0 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.46 [0.02, 13.75] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.23 [0.01, 5.10] | | < 1 | | 0% | 1 study (1/-) | 82.1 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.84 [0.06, 55.23] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 0.23 [0.01, 5.10] | | < 1 | | 0% | 1 study (1/-) | 82.1 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 0.23 [0.01, 5.10] | | < 1 | | 0% | 1 study (1/-) | 82.1 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 0.46 [0.02, 13.75] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 0.92 [0.06, 14.80] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Nephritis TRAE (grade 3-4) | 0.46 [0.02, 13.75] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Paraesthesia TRAE (grade 3-4) | 0.46 [0.02, 13.75] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 0.46 [0.02, 13.75] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
Pruritic rash TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Uveitis TRAE (grade 3-4) | 0.92 [0.02, 46.58] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 1.84 [0.06, 55.23] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.46 [0.02, 13.75] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |